The Scripps Research Institute - Lead Identification Lead ID Home Work With Us

Work With Us


Working With Us

For academic collaborators, a popular way to access our expertise and facilities is through NIH-sponsored mechanisms. Industrial and academic collaborators can also directly sponsor specific screening activities. Please contact us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call us at either (561) 228-2150 or (561) 228-2101 if you have any questions or need assistance with any of the opportunities listed below.

 

NIH-Funded Opportunities

The NIH has announced grant opportunities that fund the screening of Scripps' Drug Discovery Library. This 640,000 compound library is unique to Scripps. Please click on the links below to be directed to information related to each grant:

High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 - Clinical Trials Not Allowed)
arrow RFA-DA-22-006

Posted Date: February 4, 2021
Expiration Date: September 16, 2021
Participating Organizations: NIH
Funding Opportunity Purpose: This FOA will support high-throughput screening approaches to identify novel receptors, signal transducers, or small molecules that modulate Substance Use Disorder (SUD)-relevant signal transduction pathways (dopamine, opioid, cannabinoid, nicotinic, or other appropriately justified pathway). Applicants may also propose secondary screens and/or validation of high value identified targets.

HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)
arrow RFA-NS-21-015

Posted Date: March 11, 2021
Expiration Date: October 11, 2023
Participating Organizations: NIH
Funding Opportunity Purpose: This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award, there is no opportunity for renewal of this award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound assays. If the data does not currently exist, the application must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease.

This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered. Projects to develop analgesics for a combination of chronic overlapping pain conditions or for specific disease or pathological conditions will also be considered. Projects that seek to identify pain treatment targets in specific populations such as women, children, older adults, and other underrepresented groups will also be responsive to this FOA. Input from patients and caregivers on the therapeutic goals of the project is encouraged. The goal of each 5-year U19 application should be to identify candidate therapeutic(s) that will be ready to be submitted to RFA-NS-21-010 for further optimization.

HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)
arrow RFA-NS-21-016

Posted Date: March 11, 2021
Expiration Date: October 11, 2023
Participating Organizations: NIH
Funding Opportunity Purpose: The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed).Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a research team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
arrow PAR-21-124

Posted Date: March 12, 2021
Expiration Date: February 21, 2024
Participating Organizations: NIH, NINDS, NCCIH
Funding Opportunity Purpose: This FOA is intended to support: 1) development of new in vitro and/or ex vivo assays, and 2) screening efforts to identify and characterize novel therapeutic agents for neurological or neuromuscular disorders. These activities include (but are not limited to) set up and optimization, standardization, and validation of measures of fundamental cellular/molecular events such as binding, bioactivity at the target, and activity downstream of the target relevant to neurological function. The R61 phase will support the initial development, refinement, and validation of in vitro and ex vivo assays (including high throughput formats). The R33 phase will support: 1) iterative screening of potential therapeutic agents, 2) characterization of promising therapeutic agents from the screen, and may also support 3) efforts to design, prepare, and further characterize additional agents related to initial hits using a focused medicinal chemistry approach.

High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01)
arrow RFA-22-006

Posted Date: February 4, 2021
Expiration Date: September 16, 2021
Participating Organizations: NIH
Funding Opportunity Purpose: This FOA will support high-throughput screening approaches to identify novel receptors, signal transducers, or small molecules that modulate Substance Use Disorder (SUD)-relevant signal transduction pathways (dopamine, opioid, cannabinoid, nicotinic, or other appropriately justified pathway). Applicants may also propose secondary screens and/or validation of high value identified targets.

NIH Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 - Clinical Trial Optional)
arrow PAR-20-316

Posted Date: December 21, 2020
Expiration Date: September 13, 2023
Participating Organizations: NIH
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54s). The mission of the NIH CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of the research includes target and lead candidate identification and characterization, through lead candidate optimization and demonstration of in vivo efficacy consistent with the product's intended use in humans as a medical countermeasure. For applicants submitting U54 renewal applications, research under this FOA should culminate in an optimized lead compound ready for advanced development. The Centers will contain at least three research projects supported by an administrative core, up to three optional scientific cores, a research education core, and a pilot project program to support short-term innovative research and recruitment of new investigators into the field of medical countermeasures research. Each research project must include milestones that create discrete go or no-go decision points in a progressive translational study plan.

Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33)
arrow RFA-HL-20-023

Posted Date: September 9, 2019
Expiration Date: August 12, 2021
Participating Organizations: NHLBI
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic candidates.

Grand Opportunity in Medications Development for Substance-Use Disorders (U01)
arrow PAR-19-327

Posted Date: August 1, 2019
Expiration Date: September 2, 2022
Participating Organizations: NIDA
Funding Opportunity Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.

Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01)
arrow PAR-20-271

Posted Date: July 20, 2020
Expiration Date: January 8, 2023
Participating Organizations: NCI, NIDCD, NIMH
Funding Opportunity Purpose: Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.

Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set; and 4) hit-to-lead optimization.

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3)
arrow RFA-NS-21-010

Posted Date: September 16, 2020
Expiration Date: September 8, 2022
Participating Organizations: NINDS, NEI, NIAAA, NIAMS, NICHD, NIDCR, NIDDK, NIDA, NCCIH, ORWH
Funding Opportunity Purpose:The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) https://heal.nih.gov/research/clinical-research/eppic-net or other Phase II clinical studies. Applicants must have a promising biologic or small molecule hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, development of a pharmacodynamic/target engagement biomarker, assembly and filing of an Investigational New Drug (IND) application and Phase I clinical testing. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.

Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer's Disease (R01 Clinical Trial Optional)
arrow PAR-20-156

Posted Date: March 31, 2020
Expiration Date: May 8, 2023
Participating Organizations: NIA
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) enables data-driven drug repositioning and combination therapy for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by developing computational methods and data resources and/or integrating computational approaches with proof-of-concept efficacy studies in cell-based models, animal models, and/or humans.

Contraception Development Research Center Program (P50 Clinical Trial Optional)
arrow RFA-HD-22-003

Posted Date: November 19, 2020
Expiration Date: November 30, 2021
Participating Organizations: NICHD
Funding Opportunity Purpose: The primary purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary approaches towards the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Research Development Center. This FOA also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success. Additionally, it allows for behavioral and social science research projects to study contraceptive use and non-use of marketed products or products in clinical development. The Center will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
arrow RFA-HL-20-022

Posted Date: September 9, 2019
Expiration Date: August 12, 2021
Participating Organizations: NHLBI
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. Technologies may target atomic, molecular, sub-cellular, cellular and/or organ-level features. At the core of any project must be a novel analysis or targeting capability (encompassing novel devices, materials, or chemical/biochemical approaches) with an accompanying validation plan. General areas of interest include, but are not limited to, the following: Drug discovery platforms for identification of molecules that stimulate endogenous repair mechanisms.

Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional)
arrow PA-19-304

Posted Date: June 25, 2019
Expiration Date: July 17, 2022
Participating Organizations: NIH
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phase II (R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging or multiple chronic conditions in older people (e.g., sarcopenia, hearth failure with preserved ejection fraction (HFePF), immunosenescence, pulmonary fibrosis, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. Applications submitted in response to this FOA may involve novel treatment targets and/or innovative approaches for engaging known targets.

The R33 mechanism is intended to provide milestone-driven support (up to 5 years) for innovative exploratory and developmental research activities originally initiated under the R21 mechanism. Awardees from NIA's R21 T1 translational aging research program are encouraged to apply to this FOA to expand upon the translation of their candidate pharmacological interventions from prior studies. Other applicants with sufficient and strong preliminary/proof-of-concept data (equivalent to that achievable under a R21) for a novel drug target, new compound(s), or for a potential new clinical indication for an FDA-approved drug for age-related conditions are also eligible to apply to this FOA. The scope of early-stage T1 translational research activities to be conducted under the R33 is expected to vary with the stage of translation of the candidate therapeutic. Nevertheless, the R33 support should advance the experimental intervention closer to human testing (if warranted).

The development of non-pharmacological interventions is considered outside the scope of this FOA.

Applications that focus on Alzheimer's disease or its related dementias are outside the scope of this announcement.

NIA Program Project Applications (P01 Clinical Trial Optional)
arrow PA-19-314

Posted Date: July 12, 2019
Expiration Date: May 26, 2022
Participating Organizations: NIH
Funding Opportunity Purpose: The National Institute on Aging (NIA) invites the submission of investigator-initiated program project (P01) applications addressing scientific areas relevant to the NIA mission. Each application submitted to this FOA must include at least three related research projects that share a common central theme, focus, and/overall objective and an administrative core to lead the project. Revision applications should include expansion of an existing, or proposal of a new, project or projects within a program project. Revision applications may not request support beyond the end date of the parent P01 award.

Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional)
arrow PA-19-305

Posted Date: June 25, 2019
Expiration Date: July 17, 2022
Participating Organizations: NIH
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R21/R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging and/or multiple chronic conditions in older people (e.g., sarcopenia, heart failure with preserved ejection fraction (HFpEF), immunosenescence, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs.

This FOA provides support for up to two years (R21, milestone-driven exploratory phase) for preliminary, proof-of-concept studies, which is followed by up to three years of support (R33 phase) for further/expanded preclinical development of the candidate therapeutic. Applicants may request funds for the development of assays and other methodologies required for translational studies in the project budget for the R21 and/or R33 phases. Funding for the R33 phase will be contingent on successful completion of established milestones in the R21 phase.

The development of non-pharmacological interventions is considered outside the scope of this FOA.

Applications that focus on Alzheimer's disease or its related dementias are outside the scope of this announcement.

Applications using only the R21 mechanism will not be accepted under this FOA.

Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
arrow PA-19-194

Posted Date: February 22, 2019
Expiration Date: May 8, 2022
Participating Organizations: NCI
Funding Opportunity Purpose: The overall purpose of this funding opportunity announcement (FOA) is to stimulate exploratory development of novel microbial-based cancer therapies and to complement or synergize with current therapies. Research topics supported by this FOA may include, but are not limited to using microbes for novel drug delivery approaches (i.e. payload delivery of therapies, e.g., anti-cancer drug), natural or engineered non-pathogenic microbes with therapeutic potential to selectively infect and treat cancers of various organs, solid tumors, metastasis, microinvasion, hypoxic or poorly vascularized tissues not accessible to currently used chemical or monoclonal antibody drugs.

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
arrow PA-19-056

Posted Date: November 5, 2019
Expiration Date: January 8, 2022
Participating Organizations: All NIH institutes
Funding Opportunity Purpose: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Drug discovery research can be included: 1) assay development; 2) HTS/HCS primary screen implementation to identify initial screening hits (target-focused or phenotypic screens); 3) hit validation; 4.) medicinal chemistry SARs; and 5.) lead-optimization. Five years of support is adequate to support assay transfer, high throughput drug discovery, medicinal chemistry, DMPK pharmacology, target validation and MOA studies as well as preliminary in-vivo experimentation. SRMSC can coordinate all services (1-5) as needed. Entry requires identification of a target and/or phenotypic response, preliminary assay data and a source of biologics (i.e. cell line, proteins, peptides) Projects are reviewed and transferred to SRMSC to provided preliminary screening data for grant application.

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
arrow PA-19-053

Posted Date: November 5, 2018
Expiration Date: January 8, 2022
Participating Organizations: All NIH institutes
Funding Opportunity Purpose:The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Drug discovery research can be included: 1) assay development; 2.) Pilot or small library HTS screening; 3) larger HTS/HCS primary screen implementation to identify initial hits (target-focused or phenotypic screens). limited to a budget of no more than $275,000 over a maximum 2 year span.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U19)
arrow PAR-20-119

Posted Date: February 25, 2020
Expiration Date: March 26, 2022
Participating Organizations: NIMH, NIDA, NIAAA
Funding Opportunity Purpose: The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies. For NIMH, an application to this FOA can include the following projects or components ranging from ligand discovery (or early stage device development) and testing in preclinical assays through human Phase IIa studies of novel agents/devices. Examples include, but are not limited to: Ligand discovery for therapeutics development or as clinical research tools (e.g., imaging probes) for novel molecular targets implicated in mental illnesses. Partnerships between academia and industry are strongly encouraged.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U01)
arrow PAR-20-118

Posted Date: February 25, 2020
Expiration Date: March 26, 2022
Participating Organizations: NIMH, NIDA, NIAAA
Funding Opportunity Purpose: The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies. For NIMH, an application to this FOA can include the following projects or components ranging from ligand discovery (or early stage device development) and testing in preclinical assays through human Phase IIa studies of novel agents/devices. Examples include, but are not limited to: Ligand discovery for therapeutics development or as clinical research tools (e.g., imaging probes) for novel molecular targets implicated in mental illnesses. Partnerships between academia and industry are strongly encouraged.

Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21)
arrow PAR-20-253

Posted Date: July 7, 2020
Expiration Date: May 31, 2023
Participating Organizations: NINDS, NEI, NIAMS, NIDA, NIEHS
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) encourages applications for NIH Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental (R21) projects. The mission of the NIH CounterACT program is to foster and support research that will advance development of new and improved therapeutics to mitigate the health effects of chemical threats. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from theNIH CounterACT Cooperative Agreement programsor other related initiatives.

Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R43/R44)
arrow PA-18-566

Posted Date: January 12, 2018
Expiration Date: April 6, 2021
Participating Organizations: NIMH
Funding Opportunity Purpose: This FOA encourages SBIR grant applications to support research and development of particular priority research topics - complex technologies that require funding levels and durations beyond those reflected in the standard SBIR guidelines. Drug Discovery/Drug Development in Mental Illness: NIMH is specifically interested in supporting the development of pharmacologic agents, based on novel molecular CNS targets that improve function and minimize the side effects seen with current medications. In addition, compounds targeted for the treatment of pediatric or geriatric psychiatric disorders would also be of interest. Funding could support a range of activities including: development of novel ligand screening assays ( including high throughput) novel chemistry approaches and lead compound identification/optimization.

Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R41/R42)
arrow PA-18-579

Posted Date: January 12, 2018
Expiration Date: April 6, 2021
Participating Organizations: NIMH
Funding Opportunity Purpose: This FOA encourages SBIR grant applications to support research and development of particular priority research topics - complex technologies that require funding levels and durations beyond those reflected in the standard SBIR guidelines. Drug Discovery/Drug Development in Mental Illness: NIMH is specifically interested in supporting the development of pharmacologic agents, based on novel molecular CNS targets that improve function and minimize the side effects seen with current medications. In addition, compounds targeted for the treatment of pediatric or geriatric psychiatric disorders would also be of interest. Funding could support a range of activities including: development of novel ligand screening assays ( including high throughput) novel chemistry approaches and lead compound identification/optimization.

Assay development and screening for discovery of chemical probes, drugs or immunomodulators
arrow PAR-20-271

Posted Date: July 20, 2020
Expiration Date: January 8, 2023
Participating Organizations: NCI, NIDCD, NIMH
Funding Opportunity Purpose: Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set; and 4) hit-to-lead optimization.

Drug Discovery for Nervous System Disorders (R21)
arrow PAR-19-146

Posted Date: Jan 8, 2019
Expiration Date: Jan 8, 2022
Participating Organizations: NIMH, NIA, NIDA
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders.
This FOA is designed to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization to improve efficacy and pharmacokinetics ,and 4) Initial drug metabolism and pharmacokinetics (DMPK). Emphasis will be placed on projects that provide novel approaches to identify potential therapeutic agents.
The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high payoff projects that lack preliminary data may be most appropriate for this FOA.

Drug Discovery for Nervous System Disorders (R01)
arrow PAR-19-147

Posted Date: Jan 8, 2018
Expiration Date: Jan 8, 2022
Participating Organizations: NIMH, NIA, NIDA
Funding Opportunity Purpose: This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.

Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21)
arrow PAR-21-028

Posted Date: October 14, 2020
Expiration Date: January 8, 2024
Participating Organizations: NIMH, NEI, NIA, NIDA
R21 Research Project: The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds.

Through this FOA, NIH wishes to stimulate research in: 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI and/or NIA; and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.

The main emphasis of projects submitted under this FOA should be the discovery of cell-based chemical probes. Applicants interested in developing in vivo chemical probes may wish to apply using the companion R01 mechanism, (PAR-21-029).

Discovery of in vivo Chemical Probes for the Nervous System (R01)
arrow PAR-21-029

Posted Date: October 14, 2020
Expiration Date: January 8, 2024
Participating Organizations: NIMH, NEI, NIA, NIDA
Funding Opportunity Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds.

Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI, and/or NIA and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.

The main emphasis of projects submitted under this FOA should be the discovery of in vivo chemical probes. Applicants interested in developing cell-based chemical probes may wish to apply using the companion R21 mechanism, (PAR-21-028).

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
arrow PAR-20-122

Posted Date: March 3, 2020
Expiration Date: May 8, 2023
Participating Organizations: NINDS, NEI, NIA, NIAAA, NICHD, NIDCR, NIDA, NIMH, NCCIH
UG3/UH3 Research Project - Cooperative Agreements: The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Projects can initiate at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development.

If you have an assay you would like to screen that cannot be funded by one of the above opportunities, please e-mail us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call us at either (561) 228-2150 or (561) 228-2101 to discuss other options available to you.

 

Leadid_Robot


Scripps Florida  |  130 Scripps Way, Jupiter, FL  33458  |  (561) 228-2000
The Scripps Research Institute  |  10550 North Torrey Pines Road, La Jolla, CA  92037  |  (858) 784-1000